Status:
TERMINATED
Possible New Therapy for Advanced Cancer
Lead Sponsor:
INSYS Therapeutics Inc
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Adrenocortical Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
IL-13-PE is a chemical similar to one made by the body that is connected to a toxin to specifically attack cancer cells. Researchers want to look at different doses of IL-13-PE to find one that may be...
Eligibility Criteria
Inclusion
- Has measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria at presentation
- Has failed standard treatment
- Has met protocol-specified criteria for qualification and contraception
- Has voluntarily consented to participate and provided written informed consent prior to any protocol-specific procedures
Exclusion
- Has history or current use of over-the-counter medications, dietary supplements, or drugs outside protocol-specified parameters
- Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:
- the safety or well-being of the participant or study staff
- the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding)
- the analysis of results
Key Trial Info
Start Date :
December 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT01832974
Start Date
December 1 2012
End Date
September 1 2014
Last Update
April 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute at the National Institutes of Health
Bethesda, Maryland, United States, 20892